Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2008 Apr;25(2):207-13.
doi: 10.1007/s11239-007-0047-3. Epub 2007 May 26.

Patients with metabolic syndrome exhibit higher platelet activity than those with conventional risk factors for vascular disease

Affiliations

Patients with metabolic syndrome exhibit higher platelet activity than those with conventional risk factors for vascular disease

Victor L Serebruany et al. J Thromb Thrombolysis. 2008 Apr.

Abstract

Background: The metabolic syndrome is a matter of ongoing debate with regard to its existence, classification, clinical meaningfulness, and associated risks for vessel occlusion. Considering that persistent platelet activation is a cornerstone for the development of acute vascular events, and that patients with type 2 diabetes consistently exhibit high platelet activity, these characteristics may be critical for distinguishing and triageing specific features of metabolic syndrome among established risk factors for vascular disease.

Methods: We assessed the platelet activity by conventional aggregation, expression of major surface receptors by flow cytometry, and quantitatively by rapid bedside analyzers in 20 aspirin-naïve patients with documented metabolic syndrome, and compared these with 20 untreated subjects with multiple cardiovascular risk factors.

Results: Closure time by the PFA-100 analyzer was significantly (P = 0.002) shorter in patients with metabolic syndrome indicating platelet inhibition under high shear conditions. Ultegra analyzer readings revealed increased fibrinogen binding (P = 0.0003) what in combination with the increased expression of PAC-1 (P = 0.32) strongly suggest activation of platelet glycoprotein IIb/IIIa receptor. Surface expression of CD107a (P = 0.014), and SPAN-12 (P = 0.003) were also higher in patients with metabolic syndrome. In contrast, platelet aggregation induced by collagen or ADP, CD31, CD41, CD42b, CD51/61, CD62p, CD63, CD154, CD165, so as formation of platelet-monocyte aggregates, PAR-1 thrombin receptor, and thrombospondin did not differ between groups.

Conclusion: Patients with metabolic syndrome exhibited a higher degree of platelet activation than subjects with conventional risk factors for vascular disease. Conceptually, applying adequate antiplatelet strategies may reduce the risk of acute thrombotic events in these patients. Further prospective studies exploring this notion are encouraged.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Am J Cardiol. 2006 Feb 15;97(4):567-70 - PubMed
    1. Lancet. 1996 Nov 16;348(9038):1329-39 - PubMed
    1. Neurology. 2006 May 9;66(9):1344-9 - PubMed
    1. J Clin Hypertens (Greenwich). 2005 Dec;7(12):705-11; quiz 712-3 - PubMed
    1. Am Heart J. 2006 Jan;151(1):92-9 - PubMed

Publication types

LinkOut - more resources